Skip to content
Recall Observatory FDA recall evidence

Drug product

Hydralazine HCL Tablets, USP, 50 mg in a single blister package, Rx only, Manufactured in Czech Republic by: Teva Czech Industries s.r.o. Opava-Komarov, Czech Republic, Distributed by Goldline Laboratories, Sellersville, PA, NDC 00182-0555-89 (carton) and 00182-0555-00 (single blister).

D-1075-2014

December 18, 2013

Class II

Product summary

Firm
Teva Pharmaceuticals USA
Event
Event 67141
Status
Terminated
Classification
Class II
Quantity
112,800 tablets
Official record key
drug-enforcement:D-1075-2014

Official wording

Reason: Failed Impurities/Degradation Specifications:There is a potential for the tablets to be out of specification for impurities throughout shelf life.

Code information: Lot # 6A201018VA; Exp. 01/14.

Distribution pattern: Nationwide

Derived failure modes

  • Potency or specification failure

    reason.potency_specification_failure · v1.0.0

    out of specification